Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation

Blood

Volumn 109, Issue 5, 2007, Pages 1945-1952

  Isenberg, Jeff S ^a   Hyodo, Fuminori ^a   Matsumoto, Ken Ichiro ^a   Romeo, Martin J ^a   Abu Asab, Mones ^a   Tsokos, Maria ^a   Kuppusamy, Periannan ^b   Wink, David A ^a   Krishna, Murali C ^a   Roberts, David D ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; MYOSIN LIGHT CHAIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOSPONDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; ISCHEMIA; MOUSE; MUSCLE PERFUSION; MYOCUTANEOUS FLAP; NONHUMAN; OXIMETRY; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE RELAXATION; TISSUE NECROSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 33847372168     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-041368     Document Type: Article

References (49)

1. Brevetti G, Chiariello M. Peripheral arterial disease: the magnitude of the problem and its socioeconomic impact. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4:199-208.
2. Strandness DE Jr, Eidt JF. Peripheral vascular disease. Circulation. 2000;102:IV46-IV51.
3. Heller L, Levin LS. Lower extremity microsurgical reconstruction. Plast Reconstr Surg. 2001;108:1029-1041; quiz 1042.
4. Kuwahara M, Tada H, Mashiba K, et al. Mortality and recurrence rate after pressure ulcer operation for elderly long-term bedridden patients. Ann Plast Surg. 2005;54:629-632.
5. Castelli ML, Pecorari G, Succo G, Bena A, Andreis M, Sartoris A. Pectoralis major myocutaneous flap: analysis of complications in difficult patients. Eur Arch Otorhinolaryngol. 2001;258:542-545.
6. Weinzweig N, Gonzalez M. Free tissue failure is not an all-or-none phenomenon. Plast Reconstr Surg. 1995;96:648-660.
7. Kubo T, Yano K, Hosokawa K. Management of flaps with compromised venous outflow in head and neck microsurgical reconstruction. Microsurgery. 2002;22:391-395.
8. Ribuffo D, Chiummariello S, Cigna E, Scuderi N. Salvage of a free flap after late total thrombosis of the flap and revascularisation. Scand J Plast Reconstr Surg Hand Surg. 2004;38:50-52.
9. Murthy P, Riesberg MV, Hart S, et al. Efficacy of perioperative thromboprophylactic agents in the maintenance of anastamotic patency and survival of rat microvascular free groin flaps. Otolaryngol Head Neck Surg. 2003;129:176-182.
10. Aronow WS. Management of peripheral arterial disease. Cardiol Rev. 2005;13:61-68.
11. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
12. Murad F. Cyclic GMP: synthesis, metabolism, and function: introduction and some historical comments. Adv Pharmacol. 1994;26:1-5.
13. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21.
14. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4:53-60.
15. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des. 2003;9:521-530.
16. Higuchi H, Granger DN, Saito H, Kurose I. Assay of antioxidant and antiinflammatory activity of nitric oxide in vivo. Methods Enzymol. 1999;301:424-436.
17. Topp SG, Zhang F, Chatterjee T, Lineaweaver WC. Role of nitric oxide in surgical flap survival. J Am Coll Surg. 2005;201:628-639.
18. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003;22:63-71.
19. Favier J, Germain S, Emmerich J, Corvol P, Gasc JM. Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol. 2005;207:358-366.
20. Sezaki S, Hirohata S, Iwabu A, et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood). 2005;230:621-630.
21. Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:2935-2942.
22. Thakar CV, Zahedi K, Revelo MP, et al. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest. 2005;115:3451-3459.
23. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12.
24. Kuznetsova SA, Roberts DD. Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol. 2004;36:1126-1134.
25. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102:13141-13146.
26. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785-793.
27. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503-514.
28. Isenberg JS, Calzada MJ, Zhou L, et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol. 2005;24:110-123.
29. Afeworki M, Miller NR, Devasahayam N, et al. Preparation and EPR studies of lithium phthalocyanine radical as an oxymetric probe. Free Radic Biol Med. 1998;25:72-78.
30. Matsumoto A, Matsumoto S, Sowers AL, et al. Absolute oxygen tension (pO(2)) in murine fatty and muscle tissue as determined by EPR. Magn Reson Med. 2005;54:1530-1535.
31. Roberts DD, Cashel J, Guo N. Purification of thrombospondin from human platelets. J Tissue Cult Methods. 1994;16:217-222.
32. Li S, Moon JJ, Miao H, et al. Signal transduction in matrix contraction and the migration of vascular smooth muscle cells in three-dimensional matrix. J Vasc Res. 2003;40:378-388.
33. Ueda K, Nozawa M, Miyasaka M, Akamatsu J, Tajima S. Sulfatide protects rat skin flaps against ischemia-reperfusion injury. J Surg Res. 1998;80:200-204.
34. Krishna MC, Devasahayam N, Cook JA, Subramanian S, Kuppusamy P, Mitchell JB. Electron paramagnetic resonance for small animal imaging applications. ILAR J. 2001;42:209-218.
35. Noseworthy MD, Bulte DP, Alfonsi J. BOLD magnetic resonance imaging of skeletal muscle. Semin Musculoskelet Radiol. 2003;7:307-315.
36. Yamada K, Murugesan R, Devasahayam N, et al. Evaluation and comparison of pulsed and continuous wave radiofrequency electron paramagnetic resonance techniques for in vivo detection and imaging of free radicals. J Magn Reson. 2002;154:287-297.
37. van Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol. 2001;21:300-311.
38. Watterson KR, Ratz PH, Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal. 2005;17:289-298.
39. Bolz SS, Vogel L, Sollinger D, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation. 2003;107:3081-3087.
40. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res. 2002;91:151-157.
41. Krishna MC, English S, Yamada K, et al. Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proc Natl Acad Sci U S A. 2002;99:2216-2221.
42. Hammond DC, Brooksher RD, Mann RJ, Beernink JH. The dorsal skin-flap model in the rat: factors influencing survival. Plast Reconstr Surg. 1993;91:316-321.
43. Mullen MJ, Kharbanda RK, Cross J, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88:145-151.
44. Khiabani KT, Kerrigan CL. The effects of the nitric oxide donor SIN-1 on ischemia-reperfused cutaneous and myocutaneous flaps. Plast Reconstr Surg. 2002;110:169-176.
45. Napoli C, Williams-Ignarro S, de Nigris F, et al. Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb. Proc Natl Acad Sci U S A. 2005;102:17202-17206.
46. Knox LK, Angel MF, Gamper T, Amiss LR, Morgan RF. Secondary ischemic tolerance improved by administration of L-NAME in rat flaps. Microsurgery. 1996;17:425-427.
47. Yu J, deMuinck ED, Zhuang Z, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A. 2005;102:10999-11004.
48. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol. 2002;161:831-839.
49. Sorbera L, Bayes M. ABT-510: Oncolytic Angiogenesis Inhibitor. Drugs Future. 2005;30:1081-1086.